Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide
about
Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatmentUpdate on treatment of light chain amyloidosisPhase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis.Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.Light chain amyloidosis 2012: a new era.Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.New insights and modern treatment of AL amyloidosis.Immunoglobulin light chain amyloidosis.Future directions in the clinical management of amyloid light-chain amyloidosis.Novel strategies for the diagnosis and treatment of cardiac amyloidosis.New and developing therapies for AL amyloidosis.Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.Clinical features and treatment outcome of primary systemic light-chain amyloidosis in Korea: results of multicenter analysis.New concepts in the treatment and diagnosis of amyloidosis.Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis.At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.Light Chain Amyloidosis.Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosisOutcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant.Novel Therapies in Light Chain Amyloidosis.Recent advances in understanding and treating immunoglobulin light chain amyloidosis
P2860
Q26827340-A8317273-E506-454C-A7A1-E1D62D0E93B4Q26829735-5E78C3CD-705B-4424-99A6-B096C5B7F711Q33427726-95EEADF7-F4F6-47AB-8B83-423DFA4777CCQ34448455-C07DF94A-8B2D-46D8-8CE2-44BEE478844EQ36015183-B108B389-9C04-45FF-B12D-3EB5797390F1Q36163205-09977B18-EE91-4136-BBE4-4601A400ABBBQ36862339-9F03D6DE-CFDD-41B5-8FAF-F290C8A7B893Q38072108-7A96541D-4F86-4E66-BFE8-1C8C2EF5CD8EQ38100588-CFD193D9-E91B-4930-9956-ED890F89CFBCQ38136576-1C09F4A7-2CFA-4E93-A592-6595CDF953B3Q38172295-8E418F02-BA00-4896-9E43-785A08DE4667Q38172998-D6B31D96-BE4E-4552-810C-467C2E9334F4Q38614967-7721E909-5746-4753-BF8C-E7E73B060165Q38779623-BCB5C73E-9657-475C-8B55-422C7C006FCDQ38928383-5423E9DA-8220-443E-96A5-110F2EBA2577Q43050098-DD3BB4F9-41D2-47AF-99E0-3688756B9ABAQ46463218-52446FD5-C22E-4692-9B37-46B4075FB2DEQ46695052-466C6BCC-7179-47E5-96C8-0DC8AA690E1EQ47561519-D1403EBA-F3D2-4A97-B55E-0D2FCA9E7830Q48382207-F9A94E0E-D6CA-4336-98A0-DFE9119FA9BBQ49691497-E96861CF-DBD4-4B19-B1E2-CA4DD7A2522AQ52659305-8BABC264-749F-4DF5-B7A8-BE2EBEDD54E1Q52716575-996C32EA-C4E6-40FD-971D-EB3720D47347Q53067739-C0E57494-17CD-43D7-A77C-750DBD943610Q55127439-8CE1B9F8-CE63-429F-87D3-F8B761991188Q57166910-16AD1DD2-7ABC-46D6-A1B4-394A0323F157
P2860
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide
description
scientific article published on 30 April 2011
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2011
@uk
name
Salvage therapy with lenalidom ...... n, bortezomib, and thalidomide
@en
Salvage therapy with lenalidom ...... n, bortezomib, and thalidomide
@nl
type
label
Salvage therapy with lenalidom ...... n, bortezomib, and thalidomide
@en
Salvage therapy with lenalidom ...... n, bortezomib, and thalidomide
@nl
prefLabel
Salvage therapy with lenalidom ...... n, bortezomib, and thalidomide
@en
Salvage therapy with lenalidom ...... n, bortezomib, and thalidomide
@nl
P2093
P2860
P50
P921
P1433
P1476
Salvage therapy with lenalidom ...... n, bortezomib, and thalidomide
@en
P2093
Andrea Foli
Paola Russo
Rosangela Invernizzi
Silvia Brugnatelli
P2860
P356
10.1007/S00277-011-1244-X
P577
2011-04-30T00:00:00Z